Gastric-cancer-specific survival according to the Kaplan–Meier method.

<p>(A) HPA2110 and (B) HES9 expression and survival in gastric cancer patients.</p

The expression of HPA2110 in the subgroups of (A) stage I patients, and (B) diffuse-type in gastric cancer.

<p>The expression of HPA2110 in the subgroups of (A) stage I patients, and (B) diffuse-type in gastric cancer.</p

Cox uni- and multivariate analysis of relative risk of death from pancreatic ductal adenocarcinoma by PODXL expression.

<p>Abbrevations CI = Confidence interval, HR = Hazard ratio. Multivariate analysis included adjustment for age, gender, stage (IA-IIA, IIB and III), lymph node ratio (≥/< 20%), and perivascular invasion.</p><p>Cox uni- and multivariate analysis of relative risk of death from pancreatic ductal adenocarcinoma by PODXL expression.</p

Immunohistochemical staining pattern of PODXL by monoclonal antibody HES9 in pancreatic ductal adenocarcinoma.

<p>Representative images of PODXL expression in pancreatic ductal adenocarcinoma. (A) PODXL-negative, (B) weak cytoplasmic positivity, (C) moderate cytoplasmic positivity, and (D) strong cytoplasmic positivity. Original magnification was x 400.</p

Association of clinicopathological parameters and PODXL expression by polyclonal antibody HPA 2110.

<p>Fischer exact-test was used for 2x2 tables and linear-by-linear association test for tables with more than two rows. Missing data excluded from the analyses.</p><p>Association of clinicopathological parameters and PODXL expression by polyclonal antibody HPA 2110.</p

Immunohistochemical staining pattern of PODXL by polyclonal antibody HPA 2110 in pancreatic ductal adenocarcinoma.

<p>Representative images of PODXL expression in pancreatic ductal adenocarcinoma. (A) PODXL-negative, (B) weak cytoplasmic positivity, (C) moderate cytoplasmic positivity, and (D) strong and positive membranous positivity. Original magnification was x 400.</p

Membranous PODXL expression by polyclonal antibody HPA 2110 is a marker of poor prognosis in pancreatic ductal adenocarcinoma.

<p>Cancer-specific survival analysis according to the Kaplan-Meier method for membranous PODXL expression by the polyclonal antibody HPA 2110 in pancreatic ductal adenocarcinoma. Log-rank test was used here.</p

Association of clinicopathological parameters and PODXL expression by polyclonal antibody HPA 2110 and monoclonal antibody HES9 combined.

<p>Linear-by-linear association test was used for this table. Missing data excluded from the analyses.</p><p>Association of clinicopathological parameters and PODXL expression by polyclonal antibody HPA 2110 and monoclonal antibody HES9 combined.</p

Concomitant positivity by two PODXL antibodies.

<p>Cancer-specific survival analysis according to the Kaplan-Meier method for combined expression of PODXL by the polyclonal antibody HPA 2110 and the monoclonal antibody HES9. A categorization with three classes was created to study the two antibodies together: low (mAb, low and pAb, non-membranous), moderate (either mAb, high or pAb, membranous), and high (mAb, high and pAb, membranous).</p